Skip to main content
RVMDW logo

RVMDW · Revolution Medicines, Inc. · Holdings

Track RVMDW — free
$8.85 -0.52 (-5.55%) At close · Oct 26
Market Cap
$40.08B
Shares
214.34M
Volume · Oct 26 18.53K Avg daily vol (3M) 39.62K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 1
Total Value: $5,125
Total Shares: 448

Institutional Ownership Trend

12 quarters

Holder Concentration

Across 1 13F filers
Top Holder
100.0%
Dec 2023 → Sep 2026 · range 0.0% – 100.0%
of institutional value
Top 5
100.0%
Dec 2023 → Sep 2026 · range 0.0% – 100.0%
of institutional value
Top 10
100.0%
Dec 2023 → Sep 2026 · range 0.0% – 100.0%
of institutional value
HHI
10,000
Dec 2023 → Sep 2026 · range 0 – 10,000
Highly concentrated

Who Holds RVMDW

Last 8 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 22 filers, like-for-like change +0.3%; actively managed books +0.3%; index-like books 0.0%.

Holder type Share Filers Change
Registered adviser 32.0% 12 -21.7%
Exempt adviser 50.2% 1 +32.0%
Bank 0.0% 2 -76.0%
Holding company 0.0% 2 -1.3%
Broker-dealer 0.0% 0 —
Unknown 17.8% 5 -14.1%

The Sep 30, 2026 filing window is still open, so its bar shows only the filers that have filed so far.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Conviction and Crowding

22 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
1
4.55% of filers hold it in their top 10
Mar 31, 2026: 2
Holders above 5%
0
median weight —
Mar 31, 2026: 0
Crowding
—
shares outstanding is an issuer-wide count, not one listing's
Private-fund advisers
—
of shares outstanding
Institutional ownership
—
shares outstanding is an issuer-wide count, not one listing's
Top 10 holders
95.9%
of 13F shares, Herfindahl 0.291
Active holders
+0.3%
like-for-like share change of active filers
5% stakes on record
0
0 13D, 0 13G

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Shared Holders

Companies RVMDW's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 DNTH Dianthus Therapeutics, Inc. 31
2 COGT Cogent Biosciences, Inc. 34
3 XENE Xenon Pharmaceuticals Inc. 30
4 TNGX Tango Therapeutics, Inc. 27
5 CYTK Cytokinetics Inc 37
6 ELVN Enliven Therapeutics, Inc. 28
7 ABVX Abivax S.A. 39
8 SYRE Spyre Therapeutics, Inc. 28
9 RYTM Rhythm Pharmaceuticals, Inc. 24
10 GPCR Structure Therapeutics Inc. 24

Shareholder Targets

13F filers that own its peers but not RVMDW, quarter ended Jun 30, 2026

Found through its holder-overlap peers: DNTH, COGT, XENE, TNGX, CYTK, ELVN, ABVX, SYRE, RYTM, GPCR, BLTE, INSM, VERA, DFTX, ORKA, GLUE, ASND, PCVX, MDGL, IRON. 661 filers in all.

# Filer In peers
1 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $4,698,162,668 7 held
2 RTW INVESTMENTS, LP Registered adviser, Diversified active $3,275,933,059 13 held
3 Capital International Investors Adviser, Diversified active $1,886,746,733 6 held
4 Artisan Partners Limited Partnership Registered adviser, Diversified active $1,475,913,106 6 held
5 Deep Track Capital, LP Adviser, Diversified active $1,268,399,834 9 held
6 Fairmount Funds Management LLC Registered adviser, Concentrated $907,111,371 4 held
7 Venrock Adviser, LLC Registered adviser, Concentrated $865,143,487 5 held
8 PAULSON & CO. INC. Adviser, Concentrated $719,523,739 1 held
9 Orbis Allan Gray Ltd Unknown, Diversified active $647,875,043 1 held
10 Octagon Capital Advisors LP Registered adviser, Concentrated $590,890,079 6 held

Quarterly Activity

vs Jun 30, 2026
New
0
Increased
0
Decreased
0
Sold Out
1
Unchanged
1

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: -22
Institutional value: —
Shares held: -100.0%

Top New Positions

vs Jun 30, 2026
No new positions this quarter.

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 1 of 1
Export CSV
Holder Value (USD) % of 13F Shares Open
Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 1 filings 1 filers Visit website Investor relations